Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine-Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine.

Atogepant is a new treatment for preventing migraines. This study looked at how it helps improve daily activities. Researchers analyzed data from three large clinical trials. They focused on patient-reported outcomes using the Activity Impairment in Migraine-Diary. The trials involved participants taking atogepant or a placebo for 12 weeks. Results showed that those taking atogepant experienced early improvements in function. These improvements were measured in the first four weeks of treatment. Patients reported feeling better in their daily activities and overall physical impairment. This study highlights the importance of looking at functional outcomes. Understanding how treatments affect daily life is crucial for migraine management. Early results suggest atogepant can significantly help patients feel better quickly. Overall, this research adds to the evidence supporting atogepant as an effective preventive migraine treatment. Clinical relevance: Atogepant may provide quick improvements in daily functioning for migraine patients, enhancing overall treatment effectiveness and quality of life.